AUSTRALIAN CANCER CARE NETWORK LAUNCHES TO LINK SERVICES TO POPULATION, CLINICIANS & RESEARCHERS
Aims to reduce health system disparities and tackle cancers with low survival rates
The landscape of cancer care in Australia is set to transform with the Australian Government launch in May 2024 of the Australian Comprehensive Cancer Network (ACCN) at the Innovations Showcase event, hosted by Cancer Australia in Sydney, Australia.
The ACCN is a nationally integrated system of cancer care, aimed at enhancing patient experiences and outcomes through coordinated and equitable access, by linking to comprehensive cancer services across Australia. Anchored by Comprehensive Cancer Centres (CCCs), the ACCN strives to deliver evidence-driven prevention, diagnosis, treatment, and support to all Australians affected by cancer.
Comprehensive Cancer Centres (CCCs) will serve as anchors in the ACCN, connecting various cancer control services nationwide. Through building partnerships and harnessing virtual connectivity, CCCs will collaborate with other cancer care centres, academic institutions, Aboriginal Community Controlled Health Services, regional hospitals and allied health services, among others.
While Australia has some of the world’s highest cancer survival rates, not all people experience equal outcomes. There are significant disparities in cancer outcomes for some populations, particularly affecting those in rural and remote regions, as well as Aboriginal and Torres Strait Islander communities.
The ACCN aims to address these disparities, emphasising coordinated and equitable access to comprehensive cancer services irrespective of where a person lives, and marking a significant milestone in the advancement of cancer care in Australia.
Australian Health Journal spoke with Professor Dorothy Keefe CEO, Cancer Australia on the ACCN launch and the network being a major milestone in the Australian Cancer Plan, which was launched at the end of 2023.
Participation in the ACCN is voluntary, with services committing to a set of standards focusing on comprehensive cancer care, equitable access, research excellence, data collection, workforce development, and network connectivity. Importantly, the ACCN will complement existing networks and alliances within the cancer care landscape, fostering collaboration and maximising resources.
All services and professionals involved in cancer care are encouraged to join the ACCN and contribute to this transformative initiative.
“As part of the implementation of the Australian Cancer Plan launched in November, the ACCN represents an essential stage towards achieving our goals of improving cancer outcomes and experiences for all Australians.”, says Professor Keefe.
She points out, “To achieve world class cancer outcomes for all Australians and realise the ambition of the Australian Cancer Plan, we need collective action from all sectors of health care to address issues that contribute to variation in cancer outcomes and experience.”
-
Study reveals socioeconomic barriers to children’s healthcare access
Research published in the Australian Journal of General Practice (AJGP) has revealed mental health and developmental–behavioural issues such as ADHD are the most common paediatric referrals in metropolitan general practices.
But the research also revealed children at higher risk are less likely to get the care they may need.
-
Addressing the perinatal mental health clinician shortage
Perinatal depression and anxiety (PNDA) impacts 100,000 Australians each year, equating to one in five mums and one in ten dads, with PNDA costing Australia $877 million annually. To address the nationwide shortage of specialist perinatal mental health clinicians, Gidget Foundation Australia has partnered with Federation University to launch the Graduate Diploma in Perinatal Mental Health.
-
Using human skin hair follicles to treat Alzheimer’s disease
Professor Michael Valenzuela is a science opinion leader, innovator and creative thinker with a career-long commitment to the prevention and treatment of dementia.
Following that he completed graduate medicine and medical training at the Prince of Wales Hospital. In 2012, he established the Regenerative Neuroscience Group at the University of Sydney, and in 2017 became the university’s first Professor of Regenerative Medicine.
Professor Valenzuela’s group discovered a new cell type with potential for regenerative medicine, a rare neural precursor cell found deep within the human hair follicle. He is the main inventor on several related patents and is the Founder and Chief Scientific Officer of Skin2Neuron – a biotech company developing the first neurorestorative cell therapy for Alzheimer’s disease based on this work.
